<DOC>
	<DOCNO>NCT00575952</DOCNO>
	<brief_summary>This phase I trial study side effect best dose intraperitoneal paclitaxel give together doxorubicin hydrochloride cisplatin treat patient stage III-IV endometrial cancer . Drugs use chemotherapy , paclitaxel , doxorubicin hydrochloride , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) give different way may kill tumor cell .</brief_summary>
	<brief_title>Intraperitoneal Paclitaxel , Doxorubicin Hydrochloride , Cisplatin Treating Patients With Stage III-IV Endometrial Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose intraperitoneal ( IP ) paclitaxel give concurrently fix dose intravenous ( IV ) doxorubicin ( doxorubicin hydrochloride ) IV cisplatin . II . To determine maximum tolerate dose IP paclitaxel give concurrently fix dose IV doxorubicin hydrochloride IP cisplatin . III . To determine feasibility IV/IP base doxorubicin hydrochloride , paclitaxel , cisplatin chemotherapy regimen patient advanced endometrial cancer . OUTLINE : This dose-escalation study paclitaxel . Patients receive doxorubicin hydrochloride IV 30 minute follow cisplatin IV 1 hour day 1 , paclitaxel IV 3 hour day 2 , filgrastim subcutaneously ( SC ) day 3-12 pegfilgrastim SC day 3 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . Patients receive doxorubicin hydrochloride IV cisplatin IV IP day 1 , paclitaxel IP day 1 8 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Adenocarcinoma , Clear Cell</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients stage IIIA , stage IIIC positive cytologic washings/ascites , adnexal spread , serosal involvement , stage IV ( virtue intraperitoneal disease spread ) histologically confirm endometrial cancer ( endometrioid , serous , clear cell , squamous/adenosquamous , undifferentiated , mixed histology ) Patients must optimally cytoreduced less equal 2 cm residual disease Absolute neutrophil count ( ANC ) great equal 1,500/mm^3 , equivalent Common Toxicity Criteria ( Common Terminology Criteria Adverse Events [ CTCAE ] version 3.0 [ v3.0 ] ) grade 1 Platelets great equal 100,000/mm^3 ( CTCAE v3.0 grade 01 ) Hemoglobin great equal 10 g/dl ( CTCAE v3.0 grade 1 ) Creatinine le equal 2 mg/ % 24 hour creatinine clearance &gt; 50 ml/min Bilirubin le equal 1.5 x upper limit normal ( ULN ) ( CTCAE v3.0 grade 1 ) Serum glutamic oxaloacetic transaminase ( SGOT ) less equal 2.5 x ULN ( CTCAE v3.0 grade 1 ) Neuropathy ( sensory motor ) less equal CTCAE v3.0 grade 1 Patients must normal ejection fraction Patients must enrol within 8 week surgery Patients meet preentry requirement Patients must sign approve informed consent authorization permit release personal health information Patients must Gynecologic Oncology Group ( GOG ) performance status 0 , 1 , 2 Metastatic disease involve lung liver parenchyma , bone inguinal scalene lymph node Patients GOG performance grade 3 4 Patients concomitant medical illness serious uncontrolled infection , uncontrolled angina , serious peripheral neuropathy , opinion treat physician , make protocol prescribed treatment hazardous patient Patients 3rd degree complete heart block eligible unless pacemaker place ; patient medication alter cardiac conduction ( digitalis , beta blocker , calcium channel blocker ) cardiac conduction abnormality may place study discretion investigator Patients history invasive malignancy , exception nonmelanoma skin cancer , exclude evidence malignancy present within last five year ; patient also exclude previous cancer treatment contraindicate protocol therapy Patients receive prior radiation chemotherapy cancer treat study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>